Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.

Authors

Joe Y. Chang

The University of Texas MD Anderson Cancer Center, Houston, TX

Joe Y. Chang , Lei Feng , Steven H. Lin , James William Welsh , Mara Antonoff , Daniel Richard Gomez , John Heymach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.

First Author: Joe Y. Chang

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.

First Author: Gustavo Schvartsman

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Association of circulating CD103⁺ T cells with major pathological response in a randomized phase 2 trial of neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.

First Author: Zachary Walsh

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.

First Author: Kevin Joseph Harrington